EYPT vs. FLDM, LAB, CTKB, QTRX, PACB, NAUT, HBIO, SEER, AKYA, and BNGO
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include Fluidigm (FLDM), Standard BioTools (LAB), Cytek Biosciences (CTKB), Quanterix (QTRX), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), and Bionano Genomics (BNGO).
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Fluidigm received 65 more outperform votes than EyePoint Pharmaceuticals when rated by MarketBeat users. However, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 65.57% of users gave Fluidigm an outperform vote.
99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 76.6% of Fluidigm shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Fluidigm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Fluidigm has a net margin of -45.36% compared to EyePoint Pharmaceuticals' net margin of -157.77%. Fluidigm's return on equity of -40.15% beat EyePoint Pharmaceuticals' return on equity.
EyePoint Pharmaceuticals presently has a consensus price target of $33.71, suggesting a potential upside of 214.79%.
EyePoint Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
In the previous week, EyePoint Pharmaceuticals had 7 more articles in the media than Fluidigm. MarketBeat recorded 7 mentions for EyePoint Pharmaceuticals and 0 mentions for Fluidigm. EyePoint Pharmaceuticals' average media sentiment score of 0.64 beat Fluidigm's score of 0.28 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.
Fluidigm has higher revenue and earnings than EyePoint Pharmaceuticals. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.
Summary
Fluidigm beats EyePoint Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
